Search by Drug Name, NDC or Jcode
Internal Navigation
HCPCS Details
HCPC | J9347 |
Short Description | Inj, tremelimumab-actl, 1 mg |
Long Description | Injection, tremelimumab-actl, 1 mg |
Pricing indicator | 51 |
Coverage code | C |
ASC payment group code | YY |
BETOS2 code | O1D |
Action code | N |
Type of service | 1 |
Effective date | 2023-07-01 |
Date Added | 2023-07-01 |
HCPCS/NDC Cross-Walk
NDC | HCPC | Description | Drug Name | Labeler Name | HCPCS Dosage | PKG Size | PKG QTY | Bill Units | Bill Units PKG |
---|---|---|---|---|---|---|---|---|---|
00310450525 | J9347 | Inj, tremelimumab-actl, 1 mg | IMJUDO | Astrazeneca Pharmaceuticals, Lp | 1 MG | 1.25 | 1 | 25 | 25 |
00310453530 | J9347 | Inj, tremelimumab-actl, 1 mg | IMJUDO | Astrazeneca Pharmaceuticals, Lp | 1 MG | 15 | 1 | 300 | 300 |
HCPCS Billing Calculator
Dosage given to patient (per dose) | |
---|---|
HCPCS Dosage | 1 MG |
HCPCS/CPT Billing Units | 1 |
Total doses ordered | |
Billing Units | 1 |
Drug Details
-
Tremelimumab-actl injection is used in combination with durvalumab (Imfinzi) to treat hepatocellular carcinoma (HCC; a type of liver cancer) that cannot be treated with surgery. Tremelimumab-actl injection is also used in combination with durvalumab and platinum-containing chemotherapy to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Tremelimumab-actl is in a class of medications called monoclonal antibodies. It works by helping your immune system to slow or stop the growth of cancer cells.